The potential of antimicrobial peptides as biocides

International Journal of Molecular Sciences

Volumn 12, Issue 10, 2011, Pages 6566-6596

  Laverty, Garry ^a   Gorman, Sean P ^b   Gilmore, Brendan F ^b  

^a Ward Biotech Ltd   (Ireland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antimicrobial; Biocides; Peptides

Indexed keywords

2,5,7 TRI TERT BUTYL TRYPTOPHAN ARGININE BENZYL AMIDE; AMPHIBIAN ANTIMICROBIAL PEPTIDE DERIVATIVE; ANIONIC ANTIMICROBIAL PEPTIDE DERIVATIVE; BIOCIDE; BUFORIN II; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATIONIC ANTIMICROBIAL PEPTIDE DERIVATIVE; COLISTIN; DALBAVANCIN; DAPTOMYCIN; DERMASEPTIN; DROSOCIN; LANTIBIOTIC; LIPOPEPTIDE; MSI 843; NEOSPORIN; ORITAVANCIN; PLEUROCIDIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; PR 39; PYRRHOCORICIN; ULTRASHORT CATIONIC ANTIMICROBIAL PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIMICROBIAL CATIONIC PEPTIDE; DISINFECTANT AGENT;

AMINO ACID COMPOSITION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; EYE INFECTION; FUNGAL CELL; HUMAN; INTRACELLULAR SPACE; MEMBRANE DAMAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; STRUCTURE ACTIVITY RELATION; BACTERIA; CELL MEMBRANE; CELL WALL; CHEMISTRY; DRUG EFFECTS; HEMOLYSIS; METABOLISM;

ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; CELL MEMBRANE; CELL WALL; DISINFECTANTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMOLYSIS; LIPOPEPTIDES;

EID: 80055054079     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12106566     Document Type: Review

References (224)

1. Falagas, M.E.; Fragoulis, K.N.; Karydis, I. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE 2006, 1, 1-4.
2. Chambers, H.F.; Deleo, F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 2009, 7, 629-641.
3. Wenzel, R.P. The antibiotic pipeline-challenges, costs and values. N. Engl. J. Med. 2001, 523-526.
4. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs no drugs: No ESKAPE! An update from the infectious diseases society of America. Clin. Infect. Dis. 2009, 48, 1-12.
5. Rice, L.B. Do we really need new anti-infective drugs? Curr. Opin. Pharmacol. 2003, 3, 459-463.
6. Andreu, D.; Rivas, L. Animal antimicrobial peptides: An overview. Biopolymers 1998, 47, 415-433.
7. Joerger, R.D. Alternatives to antibiotics: Bacteriocins, antimicrobial peptides and bacteriophages. Poult. Sci. 2003, 82, 640-647.
8. Brown, K.L.; Hancock, R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 2006, 18, 24-30.
9. Bowdish, D.M.; Davidson, D.J.; Lau, Y.E.; Lee, K.; Scott, M.G.; Hancock, R.E. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 2005, 77, 451-459.
10. Rosenfeld, Y.; Sahl, H.G.; Shai, Y. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008, 47, 6468-6478.
11. Elsbach, P. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? J. Clin. Invest. 2003, 111, 1643-1645.
12. Yeaman, M.R.; Yount, N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55, 27-55.
13. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005, 3, 238-250.
14. Ganz, T.; Lehrer, R.I. Antibiotic peptides from higher eukaryotes: Biology and applications. Mol. Med. Today 1999, 5, 292-297.
15. Van't Hof, W.; Veerman, E.C.; Helmerhorst, E.J.; Amerongen, A.V. Antimicrobial peptides: Properties and applicability. Biol. Chem. 2001, 382, 597-619.
16. Hancock, R.E.; Diamond, G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 2000, 8, 402-410.
17. Brahmachary, M.; Krishnan, S.P.; Koh, J.L.; Khan, A.M.; Seah, S.H.; Tan, T.W.; Brusic, V.; Bajic, V.B. ANTIMIC: A database of antimicrobial sequences. Nucleic Acids Res. 2004, 32, D586-D589.
18. Hwang, P.M.; Vogel, H.J. Structure-function relationships of antimicrobial peptides. Biochem. Cell Biol. 1998, 76, 235-246.
19. Powers, J.P.; Hancock, R.E. The relationship between peptide structure and antibacterial activity. Peptides 2003, 24, 1681-1691.
20. Hilpert, K.; Elliott, M.R.; Volkmer-Engert, R.; Henklein, P.; Donini, O.; Zhou, Q.; Winkler, D.F.; Hancock, R.E. Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem. Biol. 2006, 13, 1101-1107.
21. Bisht, G.S.; Rawat, D.S.; Kumar, A.; Kumar, R.; Pasha, S. Antimicrobial activity of rationally designed amino terminal modified peptides. Bioorg. Med. Chem. Lett. 2007, 17, 4343-4346.
22. Hicks, R.P.; Bhonsle, J.B.; Venugopal, D.; Koser, B.W.; Magill, A.J. De novo design of selective antibiotic peptides by incorporation of unnatural amino acids. J. Med. Chem. 2007, 50, 3026-3036.
23. Laverty, G.; McLaughlin, M.; Shaw, C.; Gorman, S.P.; Gilmore, B.F. Antimicrobial activity of short, synthetic cationic lipopeptides. Chem. Biol. Drug Des. 2010, 75, 563-569.
24. Marshall, S.H.; Arenas, G. Antimicrobial Peptides: A natural alternative to chemical antibiotics and a potential for applied biotechnology. Electron. J. Biomed. 2003, 6, 272-284.
25. Hancock, R.E.; Brown, K.L.; Mookherjee, N. Host defence peptides from invertebrates-Emerging antimicrobial strategies. Immunobiology 2006, 211, 315-322.
26. McPhee, J.B.; Hancock, R.E. Function and therapeutic potential of host defence peptides. J. Pept. Sci. 2005, 11, 677-687.
27. Guskey, M.T.; Tsuji, B.T. A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010, 30, 80-94.
28. Zelezetsky, I.; Pag, U.; Sahl, H.G.; Tossi, A. Tuning the biological properties of amphipathic alpha-helical antimicrobial peptides: Rational use of minimal amino acid substitutions. Peptides 2005, 26, 2368-2376.
29. Thomas, S.; Karnik, S.; Barai, R.S.; Jayaraman, V.K.; Idicula-Thomas, S. CAMP: A useful resource for research on antimicrobial peptides. Nucleic Acids Res. 2010, 38, D774-D780.
30. Maloy, W.L.; Kari, U.P. Structure-activity studies on magainins and other host defense peptides. Biopolymers 1995, 37, 105-122.
31. Saberwal, G.; Nagaraj, R. Cell-lytic and antibacterial peptides that act by perturbing the barrier function of membranes: Facets of their conformational features, structure-function correlations and membrane-perturbing abilities. Biochim. Biophys. Acta 1994, 1197, 109-131.
32. Ganz, T.; Lehrer, R.I. Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. 1998, 10, 41-44.
33. Hancock, R.E.; Chapple, D.S. Peptide antibiotics. Antimicrob. Agents Chemother. 1999, 43, 1317-1323.
34. Shai, Y. From innate immunity to de-novo designed antimicrobial peptides. Curr. Pharm. Des. 2002, 8, 715-725.
35. Bhunia, A.; Domadia, P.N.; Bhattacharjya, S. Structural and thermodynamic analyses of the interaction between melittin and lipopolysaccharide. Biochim. Biophys. Acta 2007, 1768, 3282-3291.
36. Zasloff, M. Magainins, a class of antimicrobial peptides from xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 1987, 84, 5449-5453.
37. Bulet, P.; Hetru, C.; Dimarcq, J.L.; Hoffmann, D. Antimicrobial peptides in insects; Structure and function. Dev. Comp. Immunol. 1999, 23, 329-344.
38. Powers, J.P.; Rozek, A.; Hancock, R.E. Structure-activity relationships for the beta-hairpincationic antimicrobial peptide polyphemusin I. Biochim. Biophys. Acta 2004, 1698, 239-250.
39. Boman, H.G. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 1995, 13, 61-92.
40. Yang, S.T.; Yub Shin, S.Y.; Kim, Y.C.; Kim, Y.; Hahm, K.S.; Kim, J.I. Conformation-dependent antibiotic activity of tritrpticin, a cathelicidin-derived antimicrobial peptide. Biochem. Biophys. Res. Commun. 2002, 296, 1044-1050.
41. Selsted, M.E.; Novotny, M.J.; Morris, W.L.; Tang, Y.Q.; Smith, W.; Cullor, J.S. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 1992, 267, 4292-4295.
42. Kim, S.M.; Kim, J.M.; Joshi, B.P.; Cho, H.; Lee, K.H. Indolicidin-derived antimicrobial peptide analogs with greater bacterial selectivity and requirements for antibacterial and hemolytic activities. Biochim. Biophys. Acta 2009, 1794, 185-192.
43. Halevy, R.; Rozek, A.; Kolusheva, S.; Hancock, R.E.; Jelinek, R. Membrane binding and permeation by indolicidin analogs studied by a biomimetic lipid/polydiacetylene vesicle assay. Peptides 2003, 24, 1753-1761.
44. Foster, J.W.; Woodruff, H.B. Antibiotic substances produced by bacteria. Ann. N. Y. Acad. Sci. 2010, 1213, 125-136.
45. Greenhalgh, D.G. Topical antimicrobial agents for burn wounds. Clin. Plast. Surg. 2009, 36, 597-606.
46. Laforce, F.M.; Boose, D.S. Sublethal damage of Escherichia coli by lung lavage. Am. Rev. Respir. Dis. 1981, 124, 733-737.
47. LaForce, F.M.; Boose, D.S. Effect of zinc and phosphate on an antibacterial peptide isolated from lung lavage. Infect. Immun. 1984, 45, 692-696.
48. Harris, F.; Dennison, S.R.; Phoenix, D.A. Anionic antimicrobial peptides from eukaryotic organisms. Curr. Protein Pept. Sci. 2009, 10, 585-606.
49. Lai, R.; Liu, H.; Hui Lee, W.; Zhang, Y. An anionic antimicrobial peptide from toad. Bombina Maxima. Biochem. Biophys. Res. Commun. 2002, 295, 796-799.
50. Steffen, H.; Rieg, S.; Wiedemann, I.; Kalbacher, H.; Deeg, M.; Sahl, H.G.; Peschel, A.; Gotz, F.; Garbe, C.; Schittek, B. Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob. Agents Chemother. 2006, 50, 2608-2620.
51. Goumon, Y.; Lugardon, K.; Gadroy, P.; Strub, J.M.; Welters, I.D.; Stefano, G.B.; Aunis, D.; Metz-Boutigue, M.H. Processing of proenkephalin-a in bovine chromaffin cells. Identification of natural derived fragments by N-terminal sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Biol. Chem. 2000, 275, 38355-38362.
52. Diego-Garcia, E.; Batista, C.V.; Garcia-Gomez, B.I.; Lucas, S.; Candido, D.M.; Gomez-Lagunas, F.; Possani, L.D. The Brazilian scorpion Tityus costatus karsch: Genes, peptides and function. Toxicon 2005, 45, 273-283.
53. Bruhn, H.; Winkelmann, J.; Andersen, C.; Andra, J.; Leippe, M. Dissection of the mechanisms of cytolytic and antibacterial activity of lysenin, a defence protein of the annelid Eisenia Fetida. Dev. Comp. Immunol. 2006, 30, 597-606.
54. Prochazkova, P.; Silerova, M.; Felsberg, J.; Joskova, R.; Beschin, A.; de Baetselier, P.; Bilej, M. Relationship between hemolytic molecules in Eisenia Fetida earthworms. Dev. Comp. Immunol. 2006, 30, 381-392.
55. Brogden, K.A.; de Lucca, A.J.; Bland, J.; Elliott, S. Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica. Proc. Natl. Acad. Sci. USA 1996, 93, 412-416.
56. Grubor, B.; Meyerholz, D.K.; Ackermann, M.R. Collectins and cationic antimicrobial peptides of the respiratory epithelia. Vet. Pathol. 2006, 43, 595-612.
57. Schutte, B.C.; McCray, P.B., Jr. [Beta]-defensins in lung host defense. Annu. Rev. Physiol. 2002, 64, 709-748.
58. Brogden, K.A.; Ackermann, M.; McCray, P.B., Jr.; Tack, B.F. Antimicrobial peptides in animals and their role in host defences. Int. J. Antimicrob. Agents 2003, 22, 465-478.
59. Vandendriessche, L. Inhibitors of ribonuclease activity. Arch. Biochem. Biophys. 1956, 65, 347-353.
60. Sela, M. Inhibition of ribonuclease by copolymers of glutamic acid and aromatic amino acids. J. Biol. Chem. 1962, 237, 418-421.
61. Conlon, J.M.; Al-Ghaferi, N.; Abraham, B.; Leprince, J. Strategies for transformation of naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective agents. Methods 2007, 42, 349-357.
62. Conlon, J.M.; Raza, H.; Coquet, L.; Jouenne, T.; Leprince, J.; Vaudry, H.; King, J.D. Purification of peptides with differential cytolytic activities from the skin secretions of the central American frog, Lithobates Vaillanti (Ranidae). Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2009, 150, 150-154.
63. VanCompernolle, S.E.; Taylor, R.J.; Oswald-Richter, K.; Jiang, J.; Youree, B.E.; Bowie, J.H.; Tyler, M.J.; Conlon, J.M.; Wade, D.; Aiken, C.; et al. Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J. Virol. 2005, 79, 11598-11606.
64. Nicolas, P.; Mor, A. Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu. Rev. Microbiol. 1995, 49, 277-304.
65. Simmaco, M.; Mignogna, G.; Barra, D. Antimicrobial peptides from amphibian skin: What do they tell us? Biopolymers 1998, 47, 435-450.
66. Tyler, M.J.; Stone, D.J.; Bowie, J.H. A novel method for the release and collection of dermal, glandular secretions from the skin of frogs. J. Pharmacol. Toxicol. Methods 1992, 28, 199-200.
67. Nutkins, J.C.; Williams, D.H. Identification of highly acidic peptides from processing of the skin prepropeptides of Xenopus laevis. Eur. J. Biochem. 1989, 181, 97-102.
68. Mor, A.; Hani, K.; Nicolas, P. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J. Biol. Chem. 1994, 269, 31635-31641.
69. Conlon, J.M.; Kolodziejek, J.; Nowotny, N. Antimicrobial peptides from ranid frogs: Taxonomic and phylogenetic markers and a potential source of new therapeutic agents. Biochim. Biophys. Acta 2004, 1696, 1-14.
70. Tossi, A.; Sandri, L.; Giangaspero, A. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 2000, 55, 4-30.
71. Mignogna, G.; Simmaco, M.; Kreil, G.; Barra, D. Antibacterial and haemolytic peptides containing d-alloisoleucine from the skin of Bombina variegata. EMBO J. 1993, 12, 4829-4832.
72. Clark, D.P.; Durell, S.; Maloy, W.L.; Zasloff, M. Ranalexin. A novel antimicrobial peptide from bullfrog (Rana Catesbeiana) skin, structurally related to the bacterial antibiotic, polymyxin. J. Biol. Chem. 1994, 269, 10849-10855.
73. Mor, A.; Nguyen, V.H.; Delfour, A.; Migliore-Samour, D.; Nicolas, P. Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. Biochemistry 1991, 30, 8824-8830.
74. Raftery, M.J.; Waugh, R.J.; Bowie, J.H.; Wallace, J.C.; Tyler, M.J. The structures of the frenatin peptides from the skin secretion of the giant tree frog Litoria infrafrenata. J. Pept. Sci. 1996, 2, 117-124.
75. Lee, W.H.; Li, Y.; Lai, R.; Li, S.; Zhang, Y.; Wang, W. Variety of antimicrobial peptides in the bombina maxima toad and evidence of their rapid diversification. Eur. J. Immunol. 2005, 35, 1220-1229.
76. Lai, R.; Zheng, Y.T.; Shen, J.H.; Liu, G.J.; Liu, H.; Lee, W.H.; Tang, S.Z.; Zhang, Y. Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. Peptides 2002, 23, 427-435.
77. Hernandez, C.; Mor, A.; Dagger, F.; Nicolas, P.; Hernandez, A.; Benedetti, E.L.; Dunia, I. Functional and structural damage in Leishmania mexicana exposed to the cationic peptide dermaseptin. Eur. J. Cell Biol. 1992, 59, 414-424.
78. Strom, M.B.; Haug, B.E.; Skar, M.L.; Stensen, W.; Stiberg, T.; Svendsen, J.S. The pharmacophore of short cationic antibacterial peptides. J. Med. Chem. 2003, 46, 1567-1570.
79. Haug, B.E.; Stensen, W.; Stiberg, T.; Svendsen, J.S. Bulky nonproteinogenic amino acids permit the design of very small and effective cationic antibacterial peptides. J. Med. Chem. 2004, 47, 4159-4162.
80. Sieber, P. Modification of tryptophan residues during acidolysis of 4-methoxy-2,3,6- trimethylbenzenesulfonyl groups. Effects of scavengers. Tetrahedron Lett. 1987, 28, 1637-1640.
81. Choi, H.; Aldrich, J.V. Comparison of methods for the fmoc solid-phase synthesis and cleavage of a peptide containing both tryptophan and arginine. Int. J. Pept. Protein Res. 1993, 42, 58-63.
82. Makovitzki, A.; Baram, J.; Shai, Y. Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: In vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 2008, 47, 10630-10636.
83. Vallon-Eberhard, A.; Makovitzki, A.; Beauvais, A.; Latge, J.P.; Jung, S.; Shai, Y. Efficient clearance of aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-Lys-Ala-DAla-Lys. Antimicrob. Agents Chemother. 2008, 52, 3118-3126.
84. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. USA 2006, 103, 15997-16002.
85. Hancock, R.E.; Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24, 1551-1557.
86. Schmidtchen, A.; Frick, I.M.; Andersson, E.; Tapper, H.; Bjorck, L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. 2002, 46, 157-168.
87. Chen, Y.; Vasil, A.I.; Rehaume, L.; Mant, C.T.; Burns, J.L.; Vasil, M.L.; Hancock, R.E.; Hodges, R.S. Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem. Biol. Drug Des. 2006, 67, 162-173.
88. Papo, N.; Oren, Z.; Pag, U.; Sahl, H.G.; Shai, Y. The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J. Biol. Chem. 2002, 277, 33913-33921.
89. Thennarasu, S.; Lee, D.K.; Tan, A.; Prasad Kari, U.; Ramamoorthy, A. Antimicrobial activity and membrane selective interactions of a synthetic lipopeptide MSI-843. Biochim. Biophys. Acta 2005, 1711, 49-58.
90. Zhang, L.; Falla, T.J. Antimicrobial peptides: Therapeutic potential. Expert Opin. Pharmacother. 2006, 7, 653-663.
91. Hilpert, K.; Volkmer-Engert, R.; Walter, T.; Hancock, R.E. High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 2005, 23, 1008-1012.
92. Haug, B.E.; Svendsen, J.S. The role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptide. J. Pept. Sci. 2001, 7, 190-196.
93. Lejon, T.; Svendsen, J.S.; Haug, B.E. Simple parameterization of non-proteinogenic amino acids for QSAR of antibacterial peptides. J. Pept. Sci. 2002, 8, 302-306.
94. Strom, M.B.; Rekdal, O.; Svendsen, J.S. Antibacterial activity of 15-residue lactoferricin derivatives. J. Pept. Res. 2000, 56, 265-274.
95. Strom, M.B.; Haug, B.E.; Rekdal, O.; Skar, M.L.; Stensen, W.; Svendsen, J.S. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem. Cell Biol. 2002, 80, 65-74.
96. Strom, M.B.; Rekdal, O.; Svendsen, J.S. The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. J. Pept. Sci. 2002, 8, 36-43.
97. Strom, M.B.; Rekdal, O.; Svendsen, J.S. Antimicrobial activity of short arginine- and tryptophan-rich peptides. J. Pept. Sci. 2002, 8, 431-437.
98. Japelj, B.; Zorko, M.; Majerle, A.; Pristovsek, P.; Sanchez-Gomez, S.; Martinez de Tejada, G.; Moriyon, I.; Blondelle, S.E.; Brandenburg, K.; Andra, J. et al. The acyl group as the central element of the structural organization of antimicrobial lipopeptide. J. Am. Chem. Soc. 2007, 129, 1022-1023.
99. Jerala, R. Synthetic lipopeptides: A novel class of anti-infectives. Expert Opin. Investig. Drugs 2007, 16, 1159-1169.
100. Avrahami, D.; Shai, Y. A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J. Biol. Chem. 2004, 279, 12277-12285.
101. Kabara, J.J.; Swieczkowski, D.M.; Conley, A.J.; Truant, J.P. Fatty acids and derivatives as antimicrobial agents. Antimicrob. Agents Chemother. 1972, 2, 23-28.
102. Kitahara, T.; Koyama, N.; Matsuda, J.; Aoyama, Y.; Hirakata, Y.; Kamihira, S.; Kohno, S.; Nakashima, M.; Sasaki, H. Antimicrobial activity of saturated fatty acids and fatty amines against methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 2004, 27, 1321-1326.
103. Shalev, D.E.; Rotem, S.; Fish, A.; Mor, A. Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K4-S4-(1-13). J. Biol. Chem. 2006, 281, 9432-9438.
104. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. N-terminal modifications of polymyxin B nonapeptide and their effect on antibacterial activity. Peptides 2001, 22, 1675-1681.
105. Malina, A.; Shai, Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem. J. 2005, 390, 695-702.
106. Arbeit, R.D.; Maki, D.; Tally, F.P.; Campanaro, E.; Eisenstein, B.I. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 2004, 38, 1673-1681.
107. Livermore, D.M. Future directions with daptomycin. J. Antimicrob. Chemother. 2008, 62, iii41-iii49.
108. Mohr, J.F.; Friedrich, L.V.; Yankelev, S.; Lamp, K.C. Daptomycin for the treatment of Enterococcal bacteraemia: Results from the Cubicin Outcomes Registry and Experience (CORE). Int. J. Antimicrob. Agents 2009, 33, 543-548.
109. Andrew, J.H.; Wale, M.C.; Wale, L.J.; Greenwood, D. The effect of cultural conditions on the activity of LY146032 against Staphylococci and Streptococci. J. Antimicrob. Chemother. 1987, 20, 213-221.
110. Chow, A.W.; Cheng, N. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria. Antimicrob. Agents Chemother. 1988, 32, 788-790.
111. Alder, J.D. Daptomycin: A new drug class for the treatment of gram-positive infections. Drugs Today (Barc.) 2005, 41, 81-90.
112. Silverman, J.A.; Mortin, L.I.; Vanpraagh, A.D.; Li, T.; Alder, J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J. Infect. Dis. 2005, 191, 2149-2152.
113. Steenbergen, J.N.; Alder, J.; Thorne, G.M.; Tally, F.P. Daptomycin: A lipopeptide antibiotic for the treatment of serious gram-positive infections. J. Antimicrob. Chemother. 2005, 55, 283-288.
114. Jung, D.; Rozek, A.; Okon, M.; Hancock, R.E. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 2004, 11, 949-957.
115. Silverman, J.A.; Perlmutter, N.G.; Shapiro, H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 47, 2538-2544.
116. Shoemaker, D.M.; Simou, J.; Roland, W.E. A review of daptomycin for injection (cubicin) in the treatment of complicated skin and skin structure infections. Ther. Clin. Risk Manag. 2006, 2, 169-174.
117. Ainsworth, G.C.; Brown, A.M.; Brownlee, G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature 1947, 160, 263.
118. Stansly, P.G.; Shepherd, R.G.; White, H.L. Polymyxin: A new chemotherapeutic agent. Johns. Hopk. Hosp. Bull. 1947, 81, 43-54.
119. Benedict, R.G.; Langlykke, A.F. Antibiotic activity of Bacillus polymyxa. J. Bacteriol. 1947, 54, 24-25.
120. Koyama, Y.; Kurosasa, A.; Tsuchiya, A.; Takakuta, K. A new antibiotic 'colistin' produced by spore-forming soil bacteria. J. Antibiot. 1950, 3, 457-458.
121. Kanazawa, K.; Sato, Y.; Ohki, K.; Okimura, K.; Uchida, Y.; Shindo, M.; Sakura, N. Contribution of each amino acid residue in polymyxin B(3) to antimicrobial and lipopolysaccharide binding activity. Chem. Pharm. Bull. (Tokyo) 2009, 57, 240-244.
122. Kwa, A.; Kasiakou, S.K.; Tam, V.H.; Falagas, M.E. Polymyxin B: Similarities to and differences from colistin (polymyxin E). Expert Rev. Anti Infect. Ther. 2007, 5, 811-821.
123. Falagas, M.E.; Kasiakou, S.K. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit. Care 2006, 10, doi:10.1186/cc3995.
124. Falagas, M.E.; Kasiakou, S.K. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 2005, 40, 1333-1341.
125. British Medical Association; Royal Pharmaceutical Society of Great Britain. British National Formulary; Pharmaceutical Press: London, UK, 2009.
126. Li, J.; Nation, R.L.; Milne, R.W.; Turnidge, J.D.; Coulthard, K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int. J. Antimicrob. Agents 2005, 25, 11-25.
127. Catchpole, C.R.; Andrews, J.M.; Brenwald, N.; Wise, R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J. Antimicrob. Chemother. 1997, 39, 255-260.
128. Vaara, M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 1992, 56, 395-411.
129. Vaara, M.; Porro, M. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob. Agents Chemother. 1996, 40, 1801-1805.
130. Clausell, A.; Garcia-Subirats, M.; Pujol, M.; Busquets, M.A.; Rabanal, F.; Cajal, Y. Gram-negative outer and inner membrane models: Insertion of cyclic cationic lipopeptides. J. Phys. Chem. B 2007, 111, 551-563.
131. Groisman, E.A.; Kayser, J.; Soncini, F.C. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J. Bacteriol. 1997, 179, 7040-7045.
132. Conrad, R.S.; Galanos, C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob. Agents Chemother. 1989, 33, 1724-1728.
133. Gilleland, H.E., Jr.; Lyle, R.D. Chemical alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates. J. Bacteriol. 1979, 138, 839-845.
134. Shand, G.H.; Anwar, H.; Brown, M.R. Outer membrane proteins of polymyxin resistant Pseudomonas aeruginosa: Effect of magnesium depletion. J. Antimicrob. Chemother. 1988, 22, 811-821.
135. Warren, H.S.; Kania, S.A.; Siber, G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 1985, 28, 107-112.
136. Cardoso, L.S.; Araujo, M.I.; Goes, A.M.; Pacifico, L.G.; Oliveira, R.R.; Oliveira, S.C. Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb. Cell. Fact. 2007, 6, 1-6.
137. Koch-Weser, J.; Sidel, V.W.; Federman, E.B.; Kanarek, P.; Finer, D.C.; Eaton, A.E. Adverse effects of sodium colistimethate. manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 1970, 72, 857-868.
138. Brown, J.M.; Dorman, D.C.; Roy, L.P. Acute renal failure due to overdosage of colistin. Med. J. Aust. 1970, 2, 923-924.
139. Falagas, M.E.; Rizos, M.; Bliziotis, I.A.; Rellos, K.; Kasiakou, S.K.; Michalopoulos, A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 2005, 5, doi:10.1186/1471-2334-5-1.
140. Bergen, P.J.; Li, J.; Rayner, C.R.; Nation, R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50, 1953-1958.
141. Matsuzaki, K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1999, 1462, 1-10.
142. Neuhaus, F.C.; Baddiley, J. A continuum of anionic charge: Structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol. Mol. Biol. Rev. 2003, 67, 686-723.
143. Muhle, S.A.; Tam, J.P. Design of gram-negative selective antimicrobial peptides. Biochemistry 2001, 40, 5777-5785.
144. Avrahami, D.; Shai, Y. Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing antimicrobial peptides: A plausible mode of action. Biochemistry 2003, 42, 14946-14956.
145. Sung, W.S.; Lee, D.G. Pleurocidin-derived antifungal peptides with selective membrane-disruption effect. Biochem. Biophys. Res. Commun. 2008, 369, 858-861.
146. Lopez-Garcia, B.; Marcos, J.F.; Abad, C.; Perez-Paya, E. Stabilisation of mixed peptide/lipid complexes in selective antifungal hexapeptides. Biochim. Biophys. Acta 2004, 1660, 131-137.
147. Jenssen, H.; Hamill, P.; Hancock, R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19, 491-511.
148. Hallock, K.J.; Lee, D.K.; Ramamoorthy, A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys. J. 2003, 84, 3052-3060.
149. Conrad, R.S.; Galanos, C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob. Agents Chemother. 1989, 33, 1724-1728.
150. Gilleland, H.E., Jr.; Lyle, R.D. Chemical alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates. J. Bacteriol. 1979, 138, 839-845.
151. Shand, G.H.; Anwar, H.; Brown, M.R. Outer membrane proteins of polymyxin resistant Pseudomonas aeruginosa: Effect of magnesium depletion. J. Antimicrob. Chemother. 1988, 22, 811-821.
152. Warren, H.S.; Kania, S.A.; Siber, G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 1985, 28, 107-112.
153. Cardoso, L.S.; Araujo, M.I.; Goes, A.M.; Pacifico, L.G.; Oliveira, R.R.; Oliveira, S.C. Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb. Cell. Fact. 2007, 6, 1-6.
154. Koch-Weser, J.; Sidel, V.W.; Federman, E.B.; Kanarek, P.; Finer, D.C.; Eaton, A.E. Adverse effects of sodium colistimethate. manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 1970, 72, 857-868.
155. Brown, J.M.; Dorman, D.C.; Roy, L.P. Acute renal failure due to overdosage of colistin. Med. J. Aust. 1970, 2, 923-924.
156. Falagas, M.E.; Rizos, M.; Bliziotis, I.A.; Rellos, K.; Kasiakou, S.K.; Michalopoulos, A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 2005, 5, doi:10.1186/1471-2334-5-1.
157. Bergen, P.J.; Li, J.; Rayner, C.R.; Nation, R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50, 1953-1958.
158. Matsuzaki, K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1999, 1462, 1-10.
159. Neuhaus, F.C.; Baddiley, J. A continuum of anionic charge: Structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol. Mol. Biol. Rev. 2003, 67, 686-723.
160. Muhle, S.A.; Tam, J.P. Design of gram-negative selective antimicrobial peptides. Biochemistry 2001, 40, 5777-5785.
161. Avrahami, D.; Shai, Y. Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing antimicrobial peptides: A plausible mode of action. Biochemistry 2003, 42, 14946-14956.
162. Sung, W.S.; Lee, D.G. Pleurocidin-derived antifungal peptides with selective membrane-disruption effect. Biochem. Biophys. Res. Commun. 2008, 369, 858-861.
163. Lopez-Garcia, B.; Marcos, J.F.; Abad, C.; Perez-Paya, E. Stabilisation of mixed peptide/lipid complexes in selective antifungal hexapeptides. Biochim. Biophys. Acta 2004, 1660, 131-137.
164. Jenssen, H.; Hamill, P.; Hancock, R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19, 491-511.
165. Hallock, K.J.; Lee, D.K.; Ramamoorthy, A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys. J. 2003, 84, 3052-3060.
166. Bellamy, W.; Wakabayashi, H.; Takase, M.; Kawase, K.; Shimamura, S.; Tomita, M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol. 1993, 182, 97-105.
167. Ajesh, K.; Sreejith, K. Peptide antibiotics: An alternative and effective antimicrobial strategy to circumvent fungal infections. Peptides 2009, 30, 999-1006.
168. Maget-Dana, R.; Peypoux, F. Iturins, a special class of pore-forming lipopeptides: Biological and physicochemical properties. Toxicology 1994, 87, 151-174.
169. Vylkova, S.; Sun, J.N.; Edgerton, M. The role of released ATP in killing Candida albicans and other extracellular microbial pathogens by cationic peptides. Purinergic Signal 2007, 3, 91-97.
170. Park, C.B.; Kim, H.S.; Kim, S.C. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 1998, 244, 253-257.
171. Boehr, D.D.; Draker, K.A.; Koteva, K.; Bains, M.; Hancock, R.E.; Wright, G.D. Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chem. Biol. 2003, 10, 189-196.
172. Falla, T.J.; Karunaratne, D.N.; Hancock, R.E. Mode of action of the antimicrobial peptide indolicidin. J. Biol. Chem. 1996, 271, 19298-19303.
173. Lee, D.G.; Kim, H.K.; Kim, S.A.; Park, Y.; Park, S.C.; Jang, S.H.; Hahm, K.S. Fungicidal effect of indolicidin and its interaction with phospholipid membranes. Biochem. Biophys. Res. Commun. 2003, 305, 305-310.
174. Ginsburg, I.; Koren, E. Are cationic antimicrobial peptides also 'double-edged swords'? Expert Rev. Anti Infect. Ther. 2008, 6, 453-462.
175. Ginsburg, I. Bactericidal cationic peptides can also function as bacteriolysis-inducing agents mimicking beta-lactam antibiotics? It is enigmatic why this concept is consistently disregarded. Med. Hypotheses 2004, 62, 367-374.
176. Boman, H.G.; Agerberth, B.; Boman, A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 1993, 61, 2978-2984.
177. Holzl, M.A.; Hofer, J.; Steinberger, P.; Pfistershammer, K.; Zlabinger, G.J. Host antimicrobial proteins as endogenous immunomodulators. Immunol. Lett. 2008, 119, 4-11.
178. Xiong, Y.Q.; Yeaman, M.R.; Bayer, A.S. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob. Agents Chemother. 1999, 43, 1111-1117.
179. Ulvatne, H.; Samuelsen, O.; Haukland, H.H.; Kramer, M.; Vorland, L.H. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol. Lett. 2004, 237, 377-384.
180. Subbalakshmi, C.; Sitaram, N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol. Lett. 1998, 160, 91-96.
181. Healy, D.P.; Gardner, J.C.; Puthoff, B.K.; Kagan, R.J.; Neely, A.N. Antibiotic-mediated bacterial filamentation: A potentially important laboratory phenomenon. Clin. Microbiol. Newsl. 2007, 29, 22-24.
182. Hsu, C.H.; Chen, C.; Jou, M.L.; Lee, A.Y.; Lin, Y.C.; Yu, Y.P.; Huang, W.T.; Wu, S.H. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: Evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res. 2005, 33, 4053-4064.
183. Iimura, M.; Gallo, R.L.; Hase, K.; Miyamoto, Y.; Eckmann, L.; Kagnoff, M.F. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 2005, 174, 4901-4907.
184. Eckmann, L. Defence molecules in intestinal innate immunity against bacterial infections. Curr. Opin. Gastroenterol. 2005, 21, 147-151.
185. Agerberth, B.; Charo, J.; Werr, J.; Olsson, B.; Idali, F.; Lindbom, L.; Kiessling, R.; Jornvall, H.; Wigzell, H.; Gudmundsson, G.H. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000, 96, 3086-3093.
186. Zanetti, M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 2004, 75, 39-48.
187. Li, J.; Post, M.; Volk, R.; Gao, Y.; Li, M.; Metais, C.; Sato, K.; Tsai, J.; Aird, W.; Rosenberg, R.D. et al. PR39, a peptide regulator of angiogenesis. Nat. Med. 2000, 6, 49-55.
188. Rotem, S.; Mor, A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 2009, 1788, 1582-1592.
189. Patrzykat, A.; Friedrich, C.L.; Zhang, L.; Mendoza, V.; Hancock, R.E. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob. Agents Chemother. 2002, 46, 605-614.
190. Park, C.B.; Kim, M.S.; Kim, S.C. A novel antimicrobial peptide from Bufo Bufo gargarizans. Biochem. Biophys. Res. Commun. 1996, 218, 408-413.
191. Piddock, L.J. Antibacterials-mechanisms of action. Curr. Opin. Microbiol. 1998, 1, 502-508.
192. Hale, J.D.; Hancock, R.E. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 2007, 5, 951-959.
193. Otvos, L., Jr.; Rogers, M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 2000, 39, 14150-14159.
194. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B.A.; Hoffmann, R.; Otvos, L., Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001, 40, 3016-3026.
195. Otvos, L., Jr.; Snyder, C.; Condie, B.; Bulet, P.; Wade, J.D. Chimeric antimicrobial peptides exhibit multiple modes of action. Int. J. Pept. Res. Ther. 2005, 11, 29-42.
196. Brotz, H.; Bierbaum, G.; Leopold, K.; Reynolds, P.E.; Sahl, H.G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 1998, 42, 154-160.
197. Brotz, H.; Sahl, H.G. New insights into the mechanism of action of lantibiotics-Diverse biological effects by binding to the same molecular target. J. Antimicrob. Chemother. 2000, 46, 1-6.
198. Marr, A.K.; Gooderham, W.J.; Hancock, R.E. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr. Opin. Pharmacol. 2006, 6, 468-472.
199. Helmerhorst, E.J.; Breeuwer, P.; van't Hof, W.; Walgreen-Weterings, E.; Oomen, L.C.; Veerman, E.C.; Amerongen, A.V.; Abee, T. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J. Biol. Chem. 1999, 274, 7286-7291.
200. Kavanagh, K.; Dowd, S. Histatins: Antimicrobial peptides with therapeutic potential. J. Pharm. Pharmacol. 2004, 56, 285-289.
201. Hodges, R.L.; Hodges, D.W.; Goggans, K.; Xuei, X.; Skatrud, P.; McGilvray, D. Genetic modification of an Echinocandin B-producing strain of Aspergillus nidulans to produce mutants blocked in sterigmatocystin biosynthesis. J. Ind. Microbiol. 1994, 13, 372-381.
202. Lorand, T.; Kocsis, B. Recent advances in antifungal agents. Mini Rev. Med. Chem. 2007, 7, 900-911.
203. Gonzalez, G.M.; Tijerina, R.; Najvar, L.K.; Bocanegra, R.; Luther, M.; Rinaldi, M.G.; Graybill, J.R. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. 2001,45, 1854-1859.
204. Douglas, C.M. Fungal beta(1,3)-D-glucan synthesis. Med. Mycol. 2001, 39, 55-66.
205. Giuliani, A.; Pirri, G.; Nicoletto, S.F. Antimicrobial peptides: An overview of a promising class of therapeutics. Eur. J. Biol. 2007, 2, 1-33.
206. Lewis, K. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 2001, 45, 999-1007.
207. Donlan, R.M. Role of biofilms in antimicrobial resistance. ASAIO J. 2000, 46, S47-S52.
208. Mulcahy, H.; Charron-Mazenod, L.; Lewenza, S. Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog. 2008, 4, 1-9.
209. Grangeasse, C.; Cozzone, A.J.; Deutscher, J.; Mijakovic, I. Tyrosine phosphorylation: An emerging regulatory device of bacterial physiology. Trends Biochem. Sci. 2007, 32, 86-94.
210. Vincent, C.; Doublet, P.; Grangeasse, C.; Vaganay, E.; Cozzone, A.J.; Duclos, B. Cells of Escherichia coli contain a protein-tyrosine kinase, wzc, and a phosphotyrosine-protein phosphatase, wzb. J. Bacteriol. 1999, 181, 3472-3477.
211. Peleg, A.; Shifrin, Y.; Ilan, O.; Nadler-Yona, C.; Nov, S.; Koby, S.; Baruch, K.; Altuvia, S.; Elgrably-Weiss, M.; Abe, C.M. et al. Identification of an Escherichia coli operon required for formation of the O-antigen capsule. J. Bacteriol. 2005, 187, 5259-5266.
212. Lacour, S.; Bechet, E.; Cozzone, A.J.; Mijakovic, I.; Grangeasse, C. Tyrosine phosphorylation of the UDP-glucose dehydrogenase of Escherichia coli is at the crossroads of colanic acid synthesis and polymyxin resistance. PLoS One 2008, 3, 1-9.
213. Pirri, G.; Giuliani, A.; Nicoletto, S.F.; Pizzuto, L.; Rinaldi, A.C. Lipopeptides as anti-infectives: A practical perspective. Cent. Eur. J. Biol. 2009, 4, 258-273.
214. Jensen, T.; Pedersen, S.S.; Garne, S.; Heilmann, C.; Hoiby, N.; Koch, C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 1987, 19, 831-838.
215. Kun, P.; Landau, L.I.; Phelan, P.D. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust. Paediatr. J. 1984, 20, 43-45.
216. Hoskin, D.W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 2008, 1778, 357-375.
217. Sambri, V.; Marangoni, A.; Giacani, L.; Gennaro, R.; Murgia, R.; Cevenini, R.; Cinco, M. Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema Pallidum. J. Antimicrob. Chemother. 2002, 50, 895-902.
218. Robinson, W.E., Jr.; McDougall, B.; Tran, D.; Selsted, M.E. Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. J. Leukoc. Biol. 1998, 63, 94-100.
219. Reddy, K.V.; Shahani, S.K.; Meherji, P.K. Spermicidal activity of magainins: In vitro and in vivo studies. Contraception 1996, 53, 205-210.
220. Yedery, R.D.; Reddy, K.V. Antimicrobial peptides as microbicidal contraceptives: Prophecies for prophylactics-A mini review. Eur. J. Contracept. Reprod. Health Care 2005, 10, 32-42.
221. Henriques, S.T.; Melo, M.N.; Castanho, M.A. Cell-penetrating peptides and antimicrobial peptides: How different are they? Biochem. J. 2006, 399, 1-7.
222. Reddy, K.V.; Yedery, R.D.; Aranha, C. Antimicrobial peptides: Premises and promises. Int. J. Antimicrob. Agents 2004, 24, 536-547.
223. Carpenter, C.F.; Chambers, H.F. Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. 2004, 38, 994-1000.
224. Oleson, F.B., Jr.; Berman, C.L.; Kirkpatrick, J.B.; Regan, K.S.; Lai, J.J.; Tally, F.P. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. 2000, 44, 2948-2953.